Tenaya Therapeutics reports interim data from gene therapy trial
Tweet Send to a Friend
Tenaya Therapeutics Inc. (NASDAQ: TNYA) reported interim safety and efficacy data from its MyPEAK-1 Phase 1b/2a clinical trial of TN-201 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




